Gemphire Therapeutics Inc (NASDAQ:GEMP) insider Steven R. Ph.D. Gullans purchased 71,429 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $7.00 per share, with a total value of $500,003.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Gemphire Therapeutics Inc (GEMP) traded down $0.12 on Monday, hitting $6.26. 209,005 shares of the stock traded hands, compared to its average volume of 128,400. Gemphire Therapeutics Inc has a 12-month low of $6.07 and a 12-month high of $21.59. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $87.89, a P/E ratio of -1.85 and a beta of 3.90.
Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.14). research analysts expect that Gemphire Therapeutics Inc will post -3.31 EPS for the current fiscal year.
GEMP has been the subject of several analyst reports. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Thursday, November 16th. HC Wainwright reissued a “buy” rating and set a $22.00 price target (up from $21.00) on shares of Gemphire Therapeutics in a research report on Tuesday, November 14th. Roth Capital reissued a “buy” rating and set a $30.00 price target on shares of Gemphire Therapeutics in a research report on Friday, December 22nd. Canaccord Genuity reissued a “buy” rating and set a $31.00 price target on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $22.00 price target on shares of Gemphire Therapeutics in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.17.
ILLEGAL ACTIVITY WARNING: “Insider Buying: Gemphire Therapeutics Inc (GEMP) Insider Purchases 71,429 Shares of Stock” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/12/insider-buying-gemphire-therapeutics-inc-gemp-insider-purchases-71429-shares-of-stock.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.